MIRA Pharmaceuticals, Inc.
MIRAMIRA Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing novel oral therapeutics for neurologic, neuropsychiatric, inflammatory, and metabolic disorders.
Table of contents
Earnings
Next report
Sep 2, 2026 (in a month)Competitors
By market cap
Profile
MIRA Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing novel oral therapeutics for neurologic, neuropsychiatric, inflammatory, and metabolic disorders. The company leverages a pipeline of small-molecule candidates designed to address significant unmet needs in neuropathic pain, obesity, and addiction. Its core value proposition lies in developing differentiated pharmacological profiles that minimize central nervous system side effects compared to existing treatments like ketamine and traditional cannabinoids.
MIRA is a clinical-stage developer positioning itself as a safer alternative to existing therapies by utilizing compounds that avoid DEA controlled-substance classification.
Questions, answered.
- What is MIRA Pharmaceuticals, Inc.'s market cap?
- MIRA Pharmaceuticals, Inc. (MIRA) has a market capitalization of $37.1M and trades on NASDAQ.
- Who are MIRA Pharmaceuticals, Inc.'s competitors?
- MIRA Pharmaceuticals, Inc.'s key competitors include Eli Lilly, Johnson & Johnson, InMed Pharmaceuticals Inc. Common Shares, and others. These companies compete in similar markets and product categories.
- Who does MIRA Pharmaceuticals, Inc. partner with?
- MIRA Pharmaceuticals, Inc.'s notable partners include Recipharm Israel Ltd., MIRALOGX, SRQ Patent Holdings II, LLC.
- What subsidiaries does MIRA Pharmaceuticals, Inc. have?
- MIRA Pharmaceuticals, Inc.'s subsidiaries include SKNY Pharmaceuticals, Inc..
- Where is MIRA Pharmaceuticals, Inc. headquartered?
- MIRA Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 6 people. It has been publicly traded since 2023.